Ensilin successfully raised over $123 million in Series E financing, bringing the total amount raised in this round to approximately $123 million.

Clinically staged biopharmaceutical technology company IngeniousAI, driven by generative artificial intelligence, announced today that it has recently completed the delivery of its Series E financing. With the support of investors, the total amount raised in this round is approximately $123 million, exceeding the set target and further demonstrating the value of the company's unique dual-engine business model, which combines generative artificial intelligence platform and deep proprietary innovation drug discovery capabilities to achieve continuous reinforcement learning and drive scientific innovation. The funds raised in this round will be used to accelerate IngeniousAI's breakthroughs in artificial intelligence platform upgrades and innovative drug development pipeline.